Skip to content
Pharma Observatory a Scientist.com platform

Molecular signature

Microsatellite stable (MSS)

Microsatellite stable (MSS) is a molecular signature biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), each linked to its source.

Matched identity
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions 1recorded FDA biomarker qualification projects Measured, none recorded Assay-provider ledger Measured, none recorded

FDA companion diagnostic

An FDA-cleared or approved companion diagnostic names this biomarker.

Get the Microsatellite stable (MSS) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Source-level evidence only

Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.

FDA companion diagnostic assertions (1)

Shown in this order: most recent decision first.

FDA companion diagnostic assertions
Diagnostic Source biomarker wording Manufacturer Indication Decision date
OncoMate MSI Dx Analysis System Microsatellite stable/MSS (Not MSI-High) Promega Corporation Endometrial Carcinoma (EC) 2025-11-05

Not on this page

Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and assay-provider ledger.

Browse all biomarker evidence pages